繁
简
Market+ (iPhone)
Market+ (Android)
Mobile Site
US STOCKS
FUNDS
FX & CRYPTO
SH/SZ-HK
HK STOCKS
 
 
 
 
 
 
Quote Service
Market
Market
Quotes
Quotes
Analysis
Analysis
Commentary
Commentary
Warrants&CBBCs
Warrants&CBBCs
Warrants&CBBCs Overview
Warrants
CBBCs
ETF
ETF
MPF
MPF
Education
Members
Members
About Us
About Us

IPO Plus - IPO

To-be Listed (Grey Market Trading Session: 14:15-16:30)
Name▼
/
Code▲
 Industry Listing Price Lot Size Entry Fee Phillip Grey Market Futu (HK) Grey Market
Minieye Tec
02431.HK
Grey Market Today
 Application Software Pending 200 4,081
-
-
 Detail Quote
Last update: 2024-12-23 12:30:04
Name▼
/
Code▼
 Industry Offer Price Lot Size Entry Fee Closing Date
Grey Market Date▼
Listing Date▲
Xunfei Healthcare
02506.HK		 Application Software 82.8 50 N/A 2024/12/23 2024/12/27 2024/12/30
InnoScience
02577.HK		 Semiconductors & Semiconductor Equipment 30.86-33.66 100 3,400 2024/12/23 2024/12/27 2024/12/30
HealthyWay
02587.HK		 Health Care Services 7.8-8.8 500 4,444 2024/12/23 2024/12/27 2024/12/30
NH HEALTH (06606.HK)
Summary
Our mission is to advance the innovation and accelerate the adoption of cancer screening technologies in China.

Founded in November 2015, we are the pioneer in China's colorectal cancer screening market with ColoClear, our proprietary, non-invasive, multi-target, FIT-DNA test, being the first and only molecular cancer screening test in China approved by NMPA, according to Frost & Sullivan. ColoClear targets a 120 million high-risk colorectal cancer population in China, and enables users to collect stool sample at home and avoid invasive procedures while delivering high testing sensitivity and specificity. In our registrational trial with 5,881 enrolled subjects, ColoClear has demonstrated clinical results of a sensitivity of 95.5% for colorectal cancer and 63.5% for advanced adenoma, an overall specificity of 87.1%, NPV of 99.6% for colorectal cancer, and PPV of 46.2% for colorectal cancer and advanced adenoma collectively. We believe that our proprietary technologies, clinical performance, regulatory and operational expertise, and solid relationships with KOLs serve as high entry barriers and differentiate us from our peers. We may not be able to fully capture the target populations of our products. As of the Latest Practicable Date, we had not commercialized ColoClear IVD.
Whether ColoClear can fully capture the 120 million high-risk colorectal cancer population in China depends on various factors, such as the commercialization of ColoClear IVD as a standalone medical device, inclusion of ColoClear under national public medical insurance program and continuous policy support from the PRC government. See “Risk Factors – Risks Relating to Commercialization and Distribution of our Products – The sizes of the markets for our current and future products have not been established with precision, and may be smaller than we estimate, and we may not be able to fully capture the target populations of our products.”

We operate in a largely untapped and fast-growing colorectal cancer screening market in China. Colorectal cancer is one of the most deadly cancer types in China, both by incidence and mortality rates. However, it is not only curable if diagnosed at early cancer stage, but also preventable if discovered at precancerous stage. In line with the PRC government's initiatives to promote cancer screening and lower expenditures on China's healthcare system, the colorectal cancer screening market in China is expected to grow significantly with the availability of more effective screening solutions and increased awareness of cancer screening. According to Frost & Sullivan, the colorectal cancer screening market in China has grown from RMB2.5 billion in 2015 to RMB3.0 billion in 2019, and is expected to further grow to RMB19.8 billion in 2030, representing a CAGR of 18.7% from 2019 to 2030. On the other hand, the colorectal cancer screening market in China remains largely untapped with a penetration rate of 16.4% in 2019, compared with 60.1% in the U.S., according to Frost & Sullivan.

To capitalize on this market opportunity and to address the unmet cancer screening demands in China, we were founded in 2015 by our experienced founders to focus on the design, development and commercialization of cancer screening tests. Our Chief Executive Officer, Mr. Yeqing Zhu, has more than 20 years of management experience in Fortune 500 multinational companies and currently serves as a council member of the Cancer Foundation of China. Our Chief Scientific Officer, Dr. Yiyou Chen, has more than 20 years of research and development experience in the oncology space, is the inventor of six patents in the U.S. and over 20 patent applications globally, and has authored multiple papers published in peerreviewed medical journals. Our Chief Technology Officer, Dr. Ning Lu, has over a decade of IVD development experience at multiple global companies, including Roche Diagnostics and Quest Diagnostics, and led the development of eight IVD products. Under their leadership, we have strategically developed a robust pipeline for cancer screening tests with a focus on vast market demand, clinical utility and technology compatibility.

Our two home-based colorectal cancer screening tests, ColoClear and Pupu Tube, synergistically address target populations with various risk levels. Pupu Tube, our proprietary, non-invasive, stool-based FIT test, is the first and only self-conducted FIT screening product approved by NMPA in China. Pupu Tube targets mass market in China with a 633 million population in 2019 recommended for colorectal cancer screening to increase colorectal cancer screening awareness and identify high-risk population. In addition, we have two late-stage product candidates for gastric and cervical cancer screening respectively. We are developing our UU Tube, a stool-based self-conducted screening test for gastric cancer. We completed the registrational trial of UU Tube in November 2020 and submitted registration application to NMPA in the same month of 2020. We are also developing our CerviClear, a non-invasive urine-based home-use screening test for cervical cancer. We expect to initiate the registrational trial for CerviClear by as early as the last quarter of 2021.

Source: New Horizon Health-B (06606) Prospectus (IPO Date : 05/02/2021)
Listing Market MAIN
Industry Biotechnology
Background Others
Major Business Area N/A
Corporate Information
Substantial Shareholders Naxin YAO & Associates (8.27%)
Yiyou CHEN & Family (7.98%)
Qiming Corporate GP V, Ltd. (7.84%)
Invesco Advisors, Inc. (7.01%)
Yeqing ZHU (6.15%)
Directors Yeqing ZHU (Co-Founder and Chairman and Chief Executive Officer and Executive Director)
Yiyou CHEN (Co-Founder and Executive Director)
Naxin YAO (Non-Executive Director)
Danke YU (Independent Non-Executive Director)
Kwok Tung LI, Donald (Independent Non-Executive Director)
Lau Ngai Kee Ricky (Independent Non-Executive Director)
Ng Weng Sin (Independent Non-Executive Director)
Jiangnan Kong (Independent Non-Executive Director)
Company Secretary Leung Wing Han Sharon
Principal Bankers China Merchants Bank
Silicon Valley Bank
Solicitors
Auditors
Registered Office 5th Floor, Manulife Place 348 Kwun Tong Road, Kowloon, Hong Kong
Share Registrars Tricor Investor Services Ltd. [Tel: (852) 2980-1333]
Share Registrars Tel No (852) 2980-1333
Internet Address https://ir.newhorizonbio.com
Email Address IR@nhbio.com.cn
Tel No (86 571) 8110-7210
Fax No (86 571) 8643-0935
 
SITEMAP
AASTOCKS.com
 
 
Members
 
About Us
Market
Quotes
 
Analysis
News & Research
 
Commentary
 
Warrants&CBBCs
 
Warrants
 
CBBCs
 
US Stocks
Forex
 
Fund
 
MPF
Email: support@aastocks.com
AASTOCKS.COM LIMITED (阿斯達克網絡信息有限公司) All rights reserved.
Disclaimer
You expressly agree that the use of this app/website is at your sole risk.

AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd, Nasdaq, Inc., their respective holding companies and/or any subsidiaries of such holding companies, their Sources and/or other third party data provider(s) endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co.Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) make any express or implied offers, representations or warranties (including, without limitation, any warranty or merchantability or fitness for a particular purpose or use) regarding the Information.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) will be liable to any Subscriber or any other party for any interruption, inaccuracy, error, or omission, regardless of cause, in the Information or for any damages (whether direct or indirect, consequential, punitive, or exemplary) resulting from its use by any party.

AASTOCKS.com Limited shall not be liable for any failure or delay in performance of its obligations under this Disclaimer because of circumstances beyond its reasonable control, including but without limitation, acts of God, typhoons, rainstorms, other natural disasters, government restrictions, strikes, wars, virus outbreak, network failures or telecommunications failures.

Morningstar Disclaimer: Copyright © 2020 Morningstar, Inc. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar and Morningstar’s third party licensors; (2) may not be copied or redistributed except as specifically authorised; (3) do not constitute investment advice; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

The information and contents contained in this app/website are based on the analyses and interpretations of publicly available information obtained from sources believed to be reliable. Such analyses and information have not been independently verified and AASTOCKS.com Limited makes no guarantees to their accuracy, completeness, timeliness or correctness.

The information, financial market data, quotes, charts, statistics, exchange rate, news, research, analysis, buy and sell ratings, Education Center and other information on this app/website should be used as references only at your own discretion. Prior to the execution of a security or any other trade based upon the Information, you are advised to consult independent professional advice to verify pricing information or to obtain more detailed market information. AASTOCKS.com Limited is not soliciting any subscriber or app/website visitor to execute any trade. Any trades executed following the said information, commentaries and/or buy/sell ratings on this app/website are taken at your own risk for your own account.

AASTOCKS.com Limited provides the information and services on an "AS IS" basis. The information and contents on this app/website are subject to change without notice. AASTOCKS.com Limited reserves the right, in its sole discretion but without any obligation, to make improvements to, or correct any error or omissions in any portion of this app/website at any time.

The subscriber or app/website visitor agrees not to reproduce, retransmit, disseminate, distribute, broadcast, publish, circulate, sell or commercially exploit the information and contents on this app/website in any manner without the express written consent of AASTOCKS.com Limited.

Investment involves risk. You may make use of the Education Center of this website for academic reference purposes at your own discretion. AASTOCKS.com Limited cannot and does not give any assurance that the present or future buy/sell commentaries and signals on this app/website will be profitable. AASTOCKS.com Limited cannot guarantee, and the subscriber or app/website visitor should not assume, that the future performance will equal past performance.

AASTOCKS.com Limited may point to other sites that may be of interest to the subscriber or app/website visitor but for which AASTOCKS.com Limited has no responsibility and only provides this as a service to the subscriber or app/website visitor.

AASTOCKS.com Limited does not represent or endorse the accuracy or reliability of any information, advertisements or contents contained on, distributed through, or linked, downloaded or accessed from any of the services on this app/website. AASTOCKS.com Limited cannot and does not guarantee the quality or reliability of any products or information purchased or obtained by you as a result of an advertisement or any other information displayed on this app/website.

AATV is a video platform owned by AASTOCKS.com Limited.

You acknowledge that: (i) AATV is provided for information purposes only and, in particular, is not intended for trading purposes; (ii) AATV does not and none of the information contained in its program constitutes a solicitation, offer, opinion, or recommendation by us to buy or sell any security, or to provide legal, tax, accounting, or investment advice or services whether or not regarding the profitability or suitability of any security or investment; and (iii) AATV is not intended for use by, or distribution to, any person or entity in any jurisdiction or country where such use or distribution would be contrary to law or regulation.

The financial analysis or opinion expressed in the AATV programs is for reference and discussion only, and does not represent AASTOCKS.com Limited. Investors must make their own investment decisions based on their own investment objectives and financial situation. AASTOCKS.com Limited shall not, directly or indirectly, be liable, in any way, to you or any other person for any: (i) inaccuracies or errors in or omissions from AATV including, but not limited to, quotes and financial data; (ii) delays, errors, or interruptions in the transmission or delivery of AATV; or (iii) loss or damage arising therefrom or occasioned thereby, or by any reason of nonperformance.

AASTOCKS.com Limited reserves the right to change this Disclaimer at any time by posting changes online at this app/website. You are responsible for reviewing regularly information posted therein to obtain timely notice of such changes. Your continued use of this app / website after changes are posted constitutes your acceptance of this Agreement as modified by the posted changes.

The disclaimer herein shall be governed by the law of the Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong") and you agree to submit to the exclusive jurisdiction of the Hong Kong courts.

In the event of any discrepancy between the Chinese and English versions, the English version shall prevail.

Last updated on 6 January 2023.